Enhanced tuberoinfundibular dopaminergic neuron activity in thyroidectomized, ovariectomized and estrogen-treated rats with hyperprolactinemia.
The involvement of the tuberoinfundibular dopaminergic (TIDA) neurons in the genesis of hyperprolactinemia in female thyroidectomized rats treated with estrogen was the focus of this study. Rats that were ovariectomized (3 weeks), thyroidectomized (2 weeks) and treated with estrogen for 6 days had a 5- to 10-fold increase in serum prolactin (PRL) levels, while the rats receiving the same treatments but without estrogen had lower PRL levels. The activity of TIDA neurons, using dihydroxyphenylacetic acid (DOPAC) concentration or the DOPAC/dopamine (DA) ratio in the median eminence (ME) as an index, was increased and decreased in estrogen-treated and untreated rats, respectively. The increases in serum PRL level and the activity of TIDA neurons were dependent on the duration of thyroidectomy and could both be lowered by daily injection of thyroid hormone (20 or 100 micrograms/kg b.w. thyroxine, i.p.) for 12 days in a dose-dependent manner. Using dihydroxyphenylalanine (DOPA) accumulation in the ME as another index, we also found an increased DOPA/DA ratio in estrogen-treated hypothyroid rats, which effect could be reversed by replacement of thyroid hormone. Furthermore, treatments with bromocryptine (3 mg/kg b.w./day, s.c.) for 3 days or with cysteamine (100 mg/kg b.w., s.c.) at 26, 15 and 2 h before the rats were sacrificed lowered both serum PRL level and TIDA neuron activity. Since PRL can exert a short-loop feedback control on its own secretion, these results indicate that the increased serum PRL levels in estrogen-treated hypothyroid female rats should be the cause, but not the result, of the increased activity of TIDA neurons.
Yang
J Y
JY
Institute of Physiology, National Yang-Ming Medical College, Taipei, Taiwan, Republic of China.
Pan
J T
JT
D015102:3,4-Dihydroxyphenylacetic Acid / Q000097:blood; D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology; D003543:Cysteamine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006966:Hyperprolactinemia / Q000503:physiopathology*; D007031:Hypothalamus / Q000503:physiopathology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010052:Ovariectomy; D011388:Prolactin / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000378:metabolism; D013965:Thyroidectomy; D013974:Thyroxine / Q000494:pharmacology
D004967:Estrogens; D011954:Receptors, Dopamine; D015102:3,4-Dihydroxyphenylacetic Acid; D001971:Bromocriptine; D003543:Cysteamine; D011388:Prolactin; D013974:Thyroxine; D004298:Dopamine